We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
-6.86%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$166M
AUM Growth
+$8.35M
Cap. Flow
+$27.8M
Cap. Flow %
16.81%
Top 10 Hldgs %
40.91%
Holding
125
New
39
Increased
43
Reduced
18
Closed
15

Top Buys

Rank Stock Value
1
MA icon
Mastercard
MA
+$4.42M
2
IWD icon
iShares Russell 1000 Value ETF
IWD
+$3.73M
3
TGNA
TEGNA Inc
TGNA
+$3.12M
4
BCYC
Bicycle Therapeutics
BCYC
+$2.8M
5
TWTR
Twitter, Inc.
TWTR
+$2.75M

Top Sells

Rank Stock Value
1
PBCT
People's United Financial Inc
PBCT
+$3.92M
2
FIS icon
Fidelity National Information Services
FIS
+$3.85M
3
CERN
Cerner Corp
CERN
+$3.49M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$1.5M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$979K

Sector Composition

Rank Sector Weight
1 Healthcare 46.47%
2 Technology 22.39%
3 Financials 16.85%
4 Communication Services 4.29%
5 Consumer Discretionary 2.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPARU
26
DELISTED
Catalyst Partners Acquisition Corp. Unit
CPARU
$1.95M 1.18%
200,000
– –
NVCR icon
27
NovoCure
NVCR
$2.02B
$1.95M 1.17%
28,007
+10,559
+61% +$795K
RLAY icon
28
Relay Therapeutics
RLAY
$4.37B
$1.9M 1.15%
113,313
+44,705
+65% +$958K
RCUS icon
29
Arcus Biosciences
RCUS
$3.66B
$1.82M 1.1%
71,650
+21,600
+43% +$529K
IDYA icon
30
IDEAYA Biosciences
IDYA
$3.54B
$1.8M 1.09%
130,380
+80,853
+163% +$899K
BMEA icon
31
Biomea Fusion
BMEA
$92.1M
$1.73M 1.05%
144,727
+31,809
+28% +$186K
DYN icon
32
Dyne Therapeutics
DYN
$4.95B
$1.66M 1%
241,867
+73,176
+43% +$504K
GBIO
33
DELISTED
Generation Bio
GBIO
$1.63M 0.99%
24,899
+11,769
+90% +$769K
CBAY
34
DELISTED
Cymabay Therapeutics
CBAY
$1.17M 0.7%
395,332
+188,025
+91% +$449K
DBC icon
35
Invesco DB Commodity Index Tracking Fund
DBC
$1.72B
$1.13M 0.68%
42,396
– –
KPTI icon
36
Karyopharm Therapeutics
KPTI
$44.4M
$1.13M 0.68%
+16,692
New +$1.53M
MSFT icon
37
Microsoft
MSFT
$3.76T
$1.02M 0.62%
+3,988
New +$1.08M
FOLD
38
DELISTED
Amicus Therapeutics
FOLD
$969K 0.59%
90,234
-18,023
-17% -$148K
BBIO icon
39
BridgeBio Pharma
BBIO
$16.6B
$962K 0.58%
105,942
+20,642
+24% +$173K
MRUS
40
DELISTED
Merus
MRUS
$916K 0.55%
40,481
+10,093
+33% +$211K
KDNY
41
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$889K 0.54%
50,834
-16,943
-25% -$266K
IMGN
42
DELISTED
Immunogen Inc
IMGN
$863K 0.52%
191,726
+114,032
+147% +$495K
EWTX icon
43
Edgewise Therapeutics
EWTX
$4.84B
$824K 0.5%
103,462
+43,729
+73% +$331K
ARGX icon
44
argenx
ARGX
$54.2B
$816K 0.49%
2,153
-908
-30% -$292K
UTHR icon
45
United Therapeutics
UTHR
$22.7B
$813K 0.49%
3,452
+795
+30% +$162K
BEAM icon
46
Beam Therapeutics
BEAM
$2.82B
$812K 0.49%
20,980
+9,878
+89% +$393K
GOSS icon
47
Gossamer Bio
GOSS
$86.1M
$810K 0.49%
96,795
+26,753
+38% +$207K
KRYS icon
48
Krystal Biotech
KRYS
$9.81B
$803K 0.48%
+12,225
New +$760K
CERE
49
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$752K 0.45%
+28,450
New +$808K
AMRN
50
Amarin Corp
AMRN
$298M
$746K 0.45%
25,034
+1,197
+5% +$51.6K
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

HighVista Strategies's Q2 2022 Portfolio in Review

As of Q2 2022, HighVista Strategies held 125 positions worth $166M, up 5.3% from $157M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

HighVista Strategies deployed $27.8M of net new capital in Q2 2022, opening 39 new positions and adding to 43 existing holdings. Its largest new stake was iShares Russell 1000 Value ETF: 23,825 shares worth $3.45M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 44% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $551K trimmed.

  • HighVista Strategies's largest Q2 2022 buy was iShares Russell 1000 Value ETF: 23,825 shares worth $3.45M.
  • HighVista Strategies added most to Mastercard in Q2 2022, an estimated $4.42M increase.
  • HighVista Strategies's biggest Q2 2022 reduction was Protagonist Therapeutics, cutting an estimated $551K.
  • HighVista Strategies fully exited People's United Financial Inc in Q2 2022, selling an estimated $3.92M.
  • HighVista Strategies's ten largest holdings make up 41% of its $166M portfolio in Q2 2022.
  • HighVista Strategies opened 39 new positions and closed 15 in Q2 2022.
  • HighVista Strategies's portfolio value rose 5.3% quarter-over-quarter to $166M.

Based on HighVista Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.